← Back to Clinical Trials
Recruiting NCT06379152

Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Heart Failure With Preserved Ejection Fraction
Sponsor Chongqing Medical University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 400
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2020-09-20
Completion 2024-06-30

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.

Eligibility Criteria

Inclusion Criteria: * Adult aged ≥18 years old; * Diagnosed with HFpEF. Diagnostic criteria including: 1. left ventricular ejection fraction ≥ 50%; 2. with the symptoms and/or signs of heart failure; 3. Patients in sinus rhythm:BNP≥35pg/ml and/or NT-proBNP≥125pg/ml;Patients with atrial fibrillation:BNP≥105pg/ml and/or NT-proBNP≥365pg/ml. Exclusion Criteria: * LVEF less than 49% at any time

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}